ATC Group: A10AE Insulins and analogues for injection, long-acting

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10AE in the ATC hierarchy

Group A10AE contents

Active ingredients in A10AE

Active Ingredient
Description

The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.

Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin. The blood glucose-lowering effect of insulin is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.

Insulin detemir is a soluble, long-acting insulin analogue with a prolonged duration of effect used as a basal insulin.

Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. After injection, the acidic solution is neutralised leading to formation of a precipitate from which small amounts of insulin glargine are continuously released.

Related product monographs

Title
Information Source
Document Type
 
FDA, National Drug Code (US)
MPI, US: SPL/PLR
European Medicines Agency (EU)
MPI, EU: SmPC
European Medicines Agency (EU)
MPI, EU: SmPC
FDA, National Drug Code (US)
MPI, US: SPL/PLR
European Medicines Agency (EU)
MPI, EU: SmPC
European Medicines Agency (EU)
MPI, EU: SmPC
European Medicines Agency (EU)
MPI, EU: SmPC
European Medicines Agency (EU)
MPI, EU: SmPC
European Medicines Agency (EU)
MPI, EU: SmPC